Interventional Cardiology Devices Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Interventional Cardiology Devices Market Report is Segmented by Product Type (Coronary Stents [Bare-Metal Stents, and More], Catheters [Angiography Catheters, and More], PTCA Balloons, Guide Wires, and More), End-User (Hospitals, Ambulatory Surgical Centers, and More), Material (Cobalt-Chromium Alloy, Nitinol, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Interventional Cardiology Devices Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Interventional Cardiology Devices Market with other markets in Healthcare Industry

Interventional Cardiology Devices Market Analysis by Mordor Intelligence

The interventional cardiology devices market generated USD 18.57 billion in 2025 and is forecast to reach USD 26.64 billion by 2030, registering a 7.48% CAGR. Current growth is anchored by brisk uptake of minimally invasive procedures that rely on drug-eluting stents, intravascular lithotripsy (IVL) systems and AI-enhanced imaging. The expanding global burden of coronary artery disease (CAD), together with same-day discharge pathways and ambulatory surgical center (ASC) adoption, continues to enlarge the addressable patient pool. Product pipelines are shifting toward thinner-strut, bio-resorbable platforms as regulators and providers place greater emphasis on long-term safety and sustainability. Competitive intensity is rising as large manufacturers pursue acquisitions that add differentiated technologies and shore up supply chains. Escalating regulatory scrutiny, workforce shortages and material legislation present headwinds but have not derailed the market’s upward trajectory.

Key Report Takeaways

  • By product type, coronary stents led with 41.35% of the interventional cardiology devices market share in 2024, while IVL systems are projected to grow at 11.25% CAGR through 2030. 
  • By end-user, hospitals commanded 67.53% share of the interventional cardiology devices market size in 2024; ASCs exhibit the fastest growth at 10.85% CAGR to 2030. 
  • By material, cobalt-chromium alloys accounted for 40.62% revenue share in 2024, whereas polymer and bio-resorbable platforms are advancing at 12.52% CAGR. 
  • By geography, North America held 41.82% of the interventional cardiology devices market in 2024, but Asia-Pacific is expanding at 12.61% CAGR through 2030.

Segment Analysis

By Product Type: IVL Systems Drive Innovation

Coronary stents generated the largest revenue, holding 41.35% of the interventional cardiology devices market in 2024, supported by durable demand for percutaneous interventions. IVL platforms, although nascent, are forecast to advance at 11.25% CAGR through 2030. The interventional cardiology devices market size for IVL technology is expected to expand markedly as heavily calcified lesions become more frequently treated percutaneously. Ultra-thin-strut drug-eluting stents and next-generation bio-absorbable scaffolds reduce restenosis and facilitate physiologic vessel healing. Bare-metal stents are now reserved for patients requiring abbreviated dual antiplatelet therapy. PTCA balloons and guidewires maintain steady volume growth, with drug-coated balloons gaining attention for in-stent restenosis management following FDA approval of the Agent platform in 2024.

Procedural adjuncts such as IVUS and OCT catheters benefit from AI overlays that refine lesion assessment and optimize device sizing. Hemostasis devices that enable immediate ambulation are integral to same-day discharge protocols. Collectively, these innovations bolster procedural efficiency and extend the clinical reach of PCI.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By End-user: ASCs Accelerate Market Shift

Hospitals represented 67.53% of market revenue in 2024 owing to infrastructure that supports high-risk interventions and 24-hour backup. ASC volumes, however, are climbing at 10.85% CAGR as Medicare reimbursement expands and clinical evidence affirms safety parity with inpatient settings. If penetration reaches half of eligible cases, health systems could save USD 200–500 million each year without compromising outcomes. The interventional cardiology devices market size for ASC procedures is poised to widen as cath-lab efficiencies and standardized protocols lower operating costs.

Hybrid cardiac catheterization laboratories blend hospital resources with ASC efficiency, offering an intermediate option for moderate-risk cases. Same-day discharge, endorsed by the American College of Cardiology, underpins this migration strategy and drives procurement of closure devices that minimize recovery time.

By Material: Bio-resorbable Platforms Gain Momentum

Cobalt-chromium alloys retained 40.62% revenue share in 2024 for their strength and fluoroscopic visibility. Platinum-chromium and nitinol alloys dominate specialized niches requiring radiopacity or self-expansion. Polymer-based and fully bio-resorbable materials are projected to grow 12.52% annually, encouraged by the “leave-nothing-behind” paradigm. Abbott’s Esprit BTK scaffold secured FDA approval in 2024, demonstrating superior limb-salvage outcomes. The interventional cardiology devices market share of eco-friendly platforms is expected to expand further as California’s impending DEHP ban compels manufacturers to reformulate plastics. Iron-based scaffolds now exhibit complete resorption within 18 months while preserving radial force, addressing earlier mechanical limitations.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

North America led the interventional cardiology devices market with 41.82% revenue in 2024 on the back of broad insurance coverage, robust clinical research networks and rapid uptake of AI-guided imaging. The region is also pioneering ASC adoption and same-day discharge for complex PCI, although FDA recall vigilance and cath-lab staffing gaps temper growth. Europe follows as a mature yet innovation-friendly arena where sustainability initiatives encourage bio-resorbable scaffolds and lower-carbon supply chains. MDR compliance costs weigh on small manufacturers, but Germany and France continue to pilot early human use of next-generation devices.

Asia-Pacific is the standout growth engine with a 12.61% forecast CAGR. China’s public insurance expansion and hospital construction boom are scaling PCI volumes, while India’s price-capped environment favors cost-effective DES platforms anchored by local production. Japan’s stringent approval process slows rollouts but commands premium pricing once clearance is secured. South Korea and Australia showcase high procedural quality and early AI integration, positioning them as secondary innovation hubs. Together these trends are set to re-shape regional competitive dynamics and redistribute future revenue pools within the interventional cardiology devices market.

Growth Rate
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The interventional cardiology devices market is moderately consolidated. Abbott, Medtronic, Boston Scientific and Johnson & Johnson collectively dominate through comprehensive portfolios and global distribution. Johnson & Johnson closed its USD 13.1 billion purchase of Shockwave Medical in 2024, gaining a leadership position in IVL technology. Teleflex announced a EUR 760 million acquisition of Biotronik’s vascular intervention unit in 2025, adding drug-coated balloons and DES capability.

R&D pipelines emphasize AI-enabled imaging, thinner-strut stents and fully absorbable materials. Medtronic’s equity option in CathWorks underscores strategic convergence between diagnostics and therapy. Smaller regional manufacturers compete on price and local regulatory agility, particularly in China and India, while private-equity roll-ups of cardiology practices in the United States are beginning to influence purchasing decisions through centralized contracting. Persistent recall events elevate reputational risk and can swiftly reshape share positions, reinforcing the importance of post-market surveillance and proactive quality management across the interventional cardiology devices industry.

Interventional Cardiology Devices Industry Leaders

  1. Cook Medical Inc.

  2. Abbott Laboratories

  3. Boston Scientific Corporation

  4. Terumo Medical Corporation

  5. Medtronic plc

  6. *Disclaimer: Major Players sorted in no particular order
Interventional Cardiology Devices Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • March 2025: Abbott initiated a 335-patient U.S. clinical trial evaluating its coronary IVL system.
  • February 2025: Teleflex agreed to acquire Biotronik’s vascular intervention business for EUR 760 million, with deal closure expected in Q3 2025.

Table of Contents for Interventional Cardiology Devices Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Prevalence of CAD & PCI Procedures
    • 4.2.2 Accelerating Shift To Minimally-Invasive Therapies
    • 4.2.3 Continuous DES Price Erosion Expanding Addressable Pool
    • 4.2.4 AI-Augmented Pre-PCI Imaging & Decision Support Adoption
    • 4.2.5 Hospital Migration To Same-Day Discharge & ASC Settings
    • 4.2.6 Sustainability Push For Fully Bio-Resorbable Platforms
  • 4.3 Market Restraints
    • 4.3.1 Stringent Multi-Region Regulatory Pathways
    • 4.3.2 Availability Of Potent First-Line Pharmacotherapy
    • 4.3.3 Global Shortage Of Cath-Lab Personnel & Interventional Cardiologists
    • 4.3.4 Anti-Plastic Legislation Challenging Polymer-Based DES Supply Chain
  • 4.4 Technological Outlook
  • 4.5 Porter's Five Forces
    • 4.5.1 Threat of New Entrants
    • 4.5.2 Bargaining Power of Buyers
    • 4.5.3 Bargaining Power of Suppliers
    • 4.5.4 Threat of Substitutes
    • 4.5.5 Intensity of Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Product Type
    • 5.1.1 Coronary Stents
    • 5.1.1.1 Bare-metal Stents
    • 5.1.1.2 Drug-eluting Stents
    • 5.1.1.3 Bio-absorbable Scaffolds
    • 5.1.2 Catheters
    • 5.1.2.1 Angiography Catheters
    • 5.1.2.2 IVUS/OCT Catheters
    • 5.1.2.3 PTCA Guiding Catheters
    • 5.1.3 PTCA Balloons
    • 5.1.4 Guidewires
    • 5.1.5 Hemostasis & Vascular Closure Devices
    • 5.1.6 Intravascular Lithotripsy (IVL) Systems
  • 5.2 By End-user
    • 5.2.1 Hospitals
    • 5.2.2 Ambulatory Surgical Centers
    • 5.2.3 Cardiac Catheterization Labs
  • 5.3 By Material
    • 5.3.1 Cobalt-Chromium Alloy
    • 5.3.2 Platinum-Chromium Alloy
    • 5.3.3 Nitinol
    • 5.3.4 Polymer/Bio-resorbable
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 South Korea
    • 5.4.3.5 Australia
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 Abbott Laboratories
    • 6.3.2 Medtronic PLC
    • 6.3.3 Boston Scientific Corp.
    • 6.3.4 B. Braun Melsungen AG
    • 6.3.5 Terumo Corp.
    • 6.3.6 Biosensors International
    • 6.3.7 Biotronik SE & Co. KG
    • 6.3.8 Cardinal Health Inc.
    • 6.3.9 Cook Medical Inc.
    • 6.3.10 Koninklijke Philips N.V.
    • 6.3.11 Edwards Lifesciences Corp.
    • 6.3.12 Nano Therapeutics Pvt. Ltd.
    • 6.3.13 Shockwave Medical Inc.
    • 6.3.14 Merit Medical Systems
    • 6.3.15 Siemens Healthineers AG
    • 6.3.16 AngioDynamics Inc.
    • 6.3.17 C. R. Bard (BD)
    • 6.3.18 MicroPort Scientific Corp.
    • 6.3.19 Alvimedica

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Interventional Cardiology Devices Market Report Scope

As per the scope of this report, interventional cardiology is the sub-specialty of cardiology that uses intravascular catheter-based techniques with fluoroscopy to treat coronary artery, valvular, and congenital cardiac diseases. The interventional cardiology devices market is segmented by product type (coronary stents (bare stents, drug-eluting stents, and bioabsorbable stents), catheters (angiography catheters, intravascular ultrasound (IVUS) catheters, and percutaneous transluminal coronary angioplasty (PTCA) guiding catheters), percutaneous transluminal coronary angioplasty (PTCA) balloons, percutaneous transluminal coronary angioplasty (PTCA) guide wires, and other product types) and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.

By Product Type Coronary Stents Bare-metal Stents
Drug-eluting Stents
Bio-absorbable Scaffolds
Catheters Angiography Catheters
IVUS/OCT Catheters
PTCA Guiding Catheters
PTCA Balloons
Guidewires
Hemostasis & Vascular Closure Devices
Intravascular Lithotripsy (IVL) Systems
By End-user Hospitals
Ambulatory Surgical Centers
Cardiac Catheterization Labs
By Material Cobalt-Chromium Alloy
Platinum-Chromium Alloy
Nitinol
Polymer/Bio-resorbable
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
By Product Type
Coronary Stents Bare-metal Stents
Drug-eluting Stents
Bio-absorbable Scaffolds
Catheters Angiography Catheters
IVUS/OCT Catheters
PTCA Guiding Catheters
PTCA Balloons
Guidewires
Hemostasis & Vascular Closure Devices
Intravascular Lithotripsy (IVL) Systems
By End-user
Hospitals
Ambulatory Surgical Centers
Cardiac Catheterization Labs
By Material
Cobalt-Chromium Alloy
Platinum-Chromium Alloy
Nitinol
Polymer/Bio-resorbable
Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current size of the interventional cardiology devices market?

The market was valued at USD 18.57 billion in 2025 and is projected to reach USD 26.64 billion by 2030.

Which product segment is expanding the fastest?

Intravascular lithotripsy systems are forecast to grow at 11.25% CAGR through 2030, the highest among all product categories.

Why are ambulatory surgical centers gaining market share?

ASC growth is fueled by Medicare reimbursement for PCI, same-day discharge protocols and potential annual cost savings of USD 200–500 million once penetration reaches 50%.

How are regulatory changes in Europe affecting device availability?

The Medical Device Regulation requires more clinical evidence and post-market surveillance, extending approval timelines and increasing compliance costs for manufacturers.

What materials are expected to dominate future stent platforms?

Polymer and fully bio-resorbable scaffolds are advancing at 12.52% CAGR, driven by favorable clinical outcomes and sustainability mandates such as California’s DEHP ban.

How significant is the workforce shortage in interventional cardiology?

The United States alone is projected to face a shortfall of 8,650 cardiologists by 2037, with rural regions experiencing the most acute gaps in catheterization lab coverage.

Page last updated on: June 25, 2025

Interventional Cardiology Devices Market Report Snapshots